Skip to Content

Stock photo from Pexels

Gilead Sciences stock soars after it touts Remdesivir trial results

An announcement this week by the US pharmaceutical company specializing in virus research and medicine, Gilead Sciences, caused a three percent jump in the S&P 500 index after the market closed, while the company's own shares moved up 15 percent.

Published: April 18, 2020, 6:37 am

    Read more

    The company’s drug, Remdesivir, originally developed for Ebola, produced “miraculous” results in 113 clinical Covid-19 cases in Chicago, leaving only 2 of the 113 patients dead. Remdesivir was incidentally ultimately found to be ineffective against Ebola.

    “The best news is that most of our patients have already been discharged, which is excellent. We had only two patients who died, ” said Kathleen Mullane, a University of Chicago infectious disease specialist who oversees the Remdesivir tests at the hospital.

    The announcement, published by a medical website, STAT, in the USA, immediately spread like wildfire and has caused global stock exchange rises. Most European exchanges opened more than three percent higher.

    Gilead is a giant company that is part of the S&P 500 index of the 500 largest US companies. Although it has developed cancer drugs in the past, it has specialized in viral research and antiviral drugs in recent years, targeting HIV and Ebola, among others.

    The company already has an Aids prevention tool on the market intended for people who are at “high sexual risk”, such as prostitutes and homosexuals.

    Apparently, the California biotech company is engaged in several concurrent clinical trials with Remdesivir, both in North America and Europe. Until these trials have been completed, there will be no certainty about the drug’s efficacy to fight Covid-19 though. Last month, President Donald Trump advocated Remdesivir as one of the remedies for America to curb the pandemic.

    Gilead reacted cautiously to the news from Chicago. “What we can say at this point is that we look forward to seeing the data from current studies as soon as it becomes available,” the company said in a statement.

    The Chicago trial data is for a total of 400 serious patients and will be released soon.

    The Chinese Institute of Virology in Wuhan, funded partly by the US, has already applied for a Chinese “use patent” on January 21, 2020 to use the drug in China on Covid-19 patients.

    Funding for the development of Remdesivir was advanced by the US taxpayer, to the tune of $79 million. Gilead also obtained a so-called “orphan drug” status for it on March 23 this year. This rating by the US FDA (Food and Drug Administration) is intended for drugs used by less than 200 000 Americans and ensures further financial and legal monopoly status for medical companies, along with tax exemptions and government fees.

    So not only did the US government pay for Gilead’s research, but the US taxpayer runs the risk of not receiving anything back from the company through taxes.

    Since more than 200 000 people will need treatment, the company relinquished its “orphan drug” status on March 25. However, Gilead Sciences retains patent rights to Remdesivir in more than 70 countries that will secure its profits.

    Former US Defense Secretary Donald Rumsfeld is but one of the politically connected investors in Gilead Sciences  that owns the rights to Tamiflu, the influenza remedy that was once the most-sought after drug in the world.

    Rumsfeld served as Gilead (Research)’s chairman from 1997 to 2001.

    Biospace reported earlier this week however that “about 25 percent of patients receiving [Remdesivir] have severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure”.

    And even worse: “Another 23 percent demonstrated evidence of liver damage on lab tests,” Biospace reported.

    A recent global survey of over 6 000 doctors found hydroxychloroquine and azithromycin rated the “most effective” treatments for coronavirus. Both these drugs are cheap and cost around $1 for a full course, while Gilead’s Remdesivir may cost around $1 000 for a full course.

    Consider donating to support our work

    Help us to produce more articles like this. FreeWestMedia is depending on donations from our readers to keep going. With your help, we expose the mainstream fake news agenda.

    Keep ​your language polite​. Readers from many different countries visit and contribute to Free West Media and we must therefore obey the rules in​,​ for example​, ​Germany. Illegal content will be deleted.

    If you have been approved to post comments without preview from FWM, you are responsible for violation​s​ of​ any​ law. This means that FWM may be forced to cooperate with authorities in a possible crime investigation.

    If your comments are subject to preview ​by FWM, please be patient. We continually review comments but depending on the time of day it can take up to several hours before your comment is reviewed.

    We reserve the right to del​ete​ comments that are offensive, contain slander or foul language, or are irrelevant to the discussion.

    Americas

    Runner dies after Brooklyn marathon, 15 others hospitalized

    New YorkA runner died on Saturday morning after completing the Brooklyn Half Marathon, authorities said. The 30-year-old man possibly went into cardiac arrest around 9 am local time and was taken to hospital, where he was pronounced dead.

    US faces biggest energy crisis in half a century

    WashingtonThe energy crisis the US is facing now may be the worst in 50 years. This was voiced by none other than the head of the US Oil and Gas Association, Tim Stewart.

    Documentary on the rigging of 2020 US election

    WashingtonAmerican political commentator Dinesh D’Souza has produced a documentary about how the 2020 US presidential election was rigged in favor of Joe Biden. Since 2 May 2022, his film has been screened in 250 theaters.

    Americans are beginning to doubt Biden’s mental capacity

    WashingtonIt turns out that the world has been making fun of President Biden for a reason. Judging by opinion polls, many American citizens believe that it is time for their geriatric leader to resign.

    New US ‘Disinformation Governance Board’ director linked to Ukraine

    WashingtonThe new managing director of a US watchdog set up to fight Russian "disinformation" advised the Ukrainian government. The US Department of Homeland Security has appointed Nina Jankowicz, previously also a propagandist for the Democratic Party.

    US food production threatened by mysterious fires in meat plants

    More and more food processing plants are going up in flames in the US. Sixteen such incidents have been recorded so far. The background is unclear, but terrorism is being ruled out.

    Being ‘non-binary’ in the US has become a gainful choice

    Palm Springs, CaliforniaIn the US, the privileging of sexual minorities compared to the "normal" rest of the population is making great strides. Being "non-binary" is a now also a lucrative choice: An amount of $1000 will be paid every month to each individual who identify as a transgender American.

    Hunter Biden funded biowarfare research of US labs in Ukraine

    WashingtonThe company linked to bioweapon gain-of-function research in Ukraine and pandemic insurance was also funded by none other than Hunter Biden. Information contained on his abandoned laptop has turned out to be reliable.

    Hungarian swimmer dismisses trans victory as an ‘unfair biological advantage’

    Transsexuals and transgenders competing in sport are praised in Western countries for their "courage". But Hungarian female swimmer Réka György does not think it is fair for men to compete against women. She was banned from Twitter for expressing a popular view.

    US Colonel: ‘We are urging Ukrainians to die needlessly’

    WashingtonIn an interview with Fox News, a retired US colonel close to Trump said the fighting in Ukraine was all but over. The Russians' goal was a neutral state, and Russia should be granted that.

    Go to archive